Idiopathic Granulomatous Mastitis Clinical Trial
— IGMOfficial title:
Idiopathic Granulomatous Mastitis
NCT number | NCT04424615 |
Other study ID # | IGM |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | October 2020 |
Est. completion date | November 2021 |
Assessment of incidence, diagnosis and treatment of idiopathic granulomatous mastitis in Assiut university hospital
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | November 2021 |
Est. primary completion date | October 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 10 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1- patients proved idiopathic granulomatous mastitis by histopathological examinaton 2 - Patients during child bearing period Exclusion Criteria: 1. - tuberculous mastitis, ductectasi, fat necrosis, fungal infection, and sarcoidosis were excluded. 2. - post-surgical granulomatous reactions against foreign material |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Bellavia M, Damiano G, Palumbo VD, Spinelli G, Tomasello G, Marrazzo A, Ficarella S, Bruno A, Sammartano A, Fiorentini T, Scio A, Maione C, Lo Monte AI. Granulomatous Mastitis during Chronic Antidepressant Therapy: Is It Possible a Conservative Therapeutic Approach? J Breast Cancer. 2012 Sep;15(3):371-2. doi: 10.4048/jbc.2012.15.3.371. Epub 2012 Sep 28. — View Citation
Garcia-Rodiguez JA, Pattullo A. Idiopathic granulomatous mastitis: a mimicking disease in a pregnant woman: a case report. BMC Res Notes. 2013 Mar 14;6:95. doi: 10.1186/1756-0500-6-95. — View Citation
Kalayci TÖ, Koruyucu MB, Apaydin M, Etit D, Varer M. Idiopathic Granulomatous Mastitis Associated with Erythema Nodosum. Balkan Med J. 2016 Mar;33(2):228-31. doi: 10.5152/balkanmedj.2015.150089. Epub 2016 Mar 1. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | clinical response rate | The clinical response is categorized into ''completely healed,'' ''inadequately healed,'' ''stable,'' ''worsened,'' or ''relapsed'' if the lesions had once healed but symptoms returned. clinical response rate [ Time Frame: six months ] The clinical response is categorized into ''completely healed,'' ''inadequately healed,'' ''stable,'' ''worsened,'' or ''relapsed'' if the lesions had once healed but symptoms returned. |
six months | |
Secondary | recurrence rate | granulomatous mastitis recurrence | two years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04096300 -
An Integrative Approach for Idiopathic Granulomatous Mastitis.
|
||
Recruiting |
NCT05852171 -
Baricitinib in Idiopathic Granulomatous Mastitis
|
Phase 2 | |
Completed |
NCT05409586 -
Risk Factors and the Role of Albumin-to-globulin Ratio in Idiopathic Granulomatous Mastitis
|
||
Recruiting |
NCT05361629 -
Idiopathic Granulomatous Mastitis Combination Therapy
|
N/A |